GNLKQ (Genelink) Cyclically Adjusted PS Ratio: (As of Sep. 03, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Genelink Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation

Genelink  (OTCPK:GNLKQ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.

Genelink Cyclically Adjusted PS Ratio Related Terms

Genelink Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Genelink's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genelink Cyclically Adjusted PS Ratio Chart

Genelink Annual Data
Trend Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Genelink Quarterly Data
Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GNLKQ vs VITIF, HSTC, NTRR: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Genelink's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Genelink Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genelink's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genelink's Cyclically Adjusted PS Ratio falls into.


Genelink Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genelink's Cyclically Adjusted Revenue per Share for the quarter that ended in Sep. 2013 is calculated as:

For example, Genelink's adjusted Revenue per Share data for the three months ended in Sep. 2013 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Sep. 2013 (Change)*Current CPI (Sep. 2013)
=0.001/234.1490*234.1490
=0.001

Current CPI (Sep. 2013) = 234.1490.

Genelink Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200312 0.002 184.300 0.003
200403 0.001 187.400 0.001
200406 0.002 189.700 0.002
200409 0.005 189.900 0.006
200412 0.002 190.300 0.002
200503 0.005 193.300 0.006
200506 0.004 194.500 0.005
200509 0.002 198.800 0.002
200512 0.001 196.800 0.001
200603 0.001 199.800 0.001
200606 0.001 202.900 0.001
200609 0.001 202.900 0.001
200612 0.001 201.800 0.001
200703 0.001 205.352 0.001
200706 0.001 208.352 0.001
200709 0.001 208.490 0.001
200712 0.000 210.036 0.000
200803 0.000 213.528 0.000
200806 0.002 218.815 0.002
200809 0.019 218.783 0.020
200812 0.042 210.228 0.047
200903 0.019 212.709 0.021
200906 0.019 215.693 0.021
200909 0.019 215.969 0.021
200912 0.019 215.949 0.021
201003 0.019 217.631 0.020
201006 0.016 217.965 0.017
201009 0.013 218.439 0.014
201012 0.011 219.179 0.012
201103 0.009 223.467 0.009
201106 0.008 225.722 0.008
201109 0.005 226.889 0.005
201112 0.004 225.672 0.004
201203 0.004 229.392 0.004
201206 0.003 229.478 0.003
201209 0.002 231.407 0.002
201212 0.002 229.601 0.002
201303 0.002 232.773 0.002
201306 0.002 233.504 0.002
201309 0.001 234.149 0.001

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Genelink Business Description

Address 8250 Exchange Drive, Suite 120, Orlando, FL, USA, 32809
Genelink Inc is a genetics-based, personal healthcare firm that has developed DNA assessments measuring personal DNA tendencies. These small differences in DNA, called SNPs can indicate genetic variants, the protein products of which may not be performing at optimal levels and can be linked to aging and other wellness issues. The company's scientists use the DNA assessments information from each client to formulate products to optimize health and wellness within normal ranges. The company has a compilation of issued and pending patents that center on using DNA analysis for the purpose of customizing nutrition and skin care formulations for wellness and anti-aging.